Johnson Dunn Capital Advisors Inc’s Aquestive Therapeutics AQST Stock Holding History

Johnson Dunn Capital Advisors Inc’s Portfolio AQST Stock Details AQST Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$74.4K	Buy	+16,075	New	+$71.4K	0.05%	152

Other funds holding AQST

BCM

Bratton Capital Management Fort Worth, Texas $45.4M AUM 17.17% 1-Year Est. Return

State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $71.4B AUM 33.43% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Janney Montgomery Scott Philadelphia, Pennsylvania $52.3B AUM 19.7% 1-Year Est. Return

Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return

Commonwealth Equity Services Waltham, Massachusetts $77B AUM 19.24% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $13.5B AUM 16.58% 1-Year Est. Return

UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

Renaissance Technologies New York $73.4B AUM 32.8% 1-Year Est. Return

Johnson Dunn Capital Advisors Inc's AQST Position: Q3 2026 in Review

Johnson Dunn Capital Advisors Inc opened a new position in Aquestive Therapeutics (AQST) in Q3 2026: 16,075 shares worth $74.4K. The stake represents 0.05% of the portfolio and ranks #152 among its holdings.

110 funds tracked by Wall St. Rank hold AQST as of Q3 2026.

Johnson Dunn Capital Advisors Inc held 16,075 shares of Aquestive Therapeutics worth $74.4K as of Q3 2026.
Aquestive Therapeutics was a new Johnson Dunn Capital Advisors Inc position in Q3 2026.
Aquestive Therapeutics made up 0.05% of Johnson Dunn Capital Advisors Inc's portfolio in Q3 2026, its #152 holding.
110 funds tracked by Wall St. Rank held Aquestive Therapeutics as of Q3 2026.

Based on Johnson Dunn Capital Advisors Inc's 13F filing for Q3 2026, filed 12 Nov 2026.